CanBas Co

CanBas Co CROIC

The Cash Return on Invested Capital (CROIC) of CanBas Co (4575.T) as of Oct 18, 2026 is -86.72 %. In the previous year, Cash Return on Invested Capital (CROIC) was -26.21 % — a change of 230.83% (lower).

CROIC

-86.72 %

YoY

230.83%

Last updated:

Cash Return on Invested Capital (CROIC) of CanBas Co is 2026 -86.72 % . Cash Return on Invested Capital (CROIC) of CanBas Co was 2025 -26.21 % . It decreases by 230.83% lower compared to the previous year.

The CanBas Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-58.36 JPY
Jan 1, 2020
-56.03 JPY
Jan 1, 2021
-57.96 JPY
Jan 1, 2022
-116.47 JPY
Jan 1, 2023
-72.40 JPY
Jan 1, 2024
-54.69 JPY
Jan 1, 2025
-26.21 JPY
Jan 1, 2026
-86.72 JPY
The CanBas Co CROIC history
YEARCROICYoY
-86.72 %+230.83%
-26.21 %-52.07%
-54.69 %-24.47%
-72.40 %-37.83%
-116.47 %+100.94%
-57.96 %+3.46%
-56.03 %-4.00%
-58.36 %-42.60%
-101.67 %+200.87%
-33.79 %-27.09%
-46.35 %+38.87%
-33.38 %-52.88%
-70.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Cash Return on Invested Capital (CROIC) of CanBas Co is -86.72 % in 2026.

Cash Return on Invested Capital (CROIC) of CanBas Co changed from -26.21 % to -86.72 %, representing a 230.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) CanBas Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CanBas Co

All Key Metrics — CanBas Co